A Non-Interventional, Post Authorisation Safety Study, to Continuously Monitor Safety and Pregnancy Outcomes in a Cohort of At-Risk Essential Thrombocythaemia (ET) Subjects Exposed to Xagrid Compared to Other Conventional Cytoreductive Treatments.

Trial Profile

A Non-Interventional, Post Authorisation Safety Study, to Continuously Monitor Safety and Pregnancy Outcomes in a Cohort of At-Risk Essential Thrombocythaemia (ET) Subjects Exposed to Xagrid Compared to Other Conventional Cytoreductive Treatments.

Completed
Phase of Trial: Phase IV

Latest Information Update: 25 Jun 2017

At a glance

  • Drugs Anagrelide (Primary)
  • Indications Essential thrombocythaemia; Pregnancy complications
  • Focus Adverse reactions
  • Acronyms EXELS
  • Sponsors Shire
  • Most Recent Events

    • 25 Jun 2017 Results (n=3460) assessing the risk of acute myeloid leukemia and non-hematological malignancies in patients treated with hydroxycarbamide or anagrelide in the EXELS study, presented at the 22nd Congress of the European Haematology Association.
    • 07 May 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 06 Feb 2014 Planned number of patients changed from 4000 to 3650 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top